Medrx Co

Medrx Co Equity Turnover

The Equity Turnover of Medrx Co (4586.T) as of Oct 23, 2026 is 0.06. In the previous year, Equity Turnover was 0.12 — a change of -47.45% (lower).

Equity Turnover

0.06

YoY

-47.45%

Last updated:

Equity Turnover of Medrx Co is 2025 0.06 . Equity Turnover of Medrx Co was 2024 0.12 . It decreases by -47.45% lower compared to the previous year.

The Medrx Co Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
0.00 JPY
Jan 1, 2019
0.09 JPY
Jan 1, 2020
0.05 JPY
Jan 1, 2021
0.00 JPY
Jan 1, 2022
0.05 JPY
Jan 1, 2023
0.02 JPY
Jan 1, 2024
0.12 JPY
Jan 1, 2025
0.06 JPY
The Medrx Co Equity Turnover history
YEAREquity TurnoverYoY
0.06-47.45%
0.12+674.59%
0.02-68.69%
0.05+1,048.68%
0.00-92.03%
0.05-39.39%
0.09+2,143.79%
0.00-95.96%
0.10+993.28%
0.01-34.30%
0.01+81.37%
0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Equity Turnover of Medrx Co is 0.06 in 2025.

Equity Turnover of Medrx Co changed from 0.12 to 0.06, representing a -47.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medrx Co

All Key Metrics — Medrx Co